Emergent BioSolutions Looks beyond Biodefence with Trubion Acquisition
Heather Cartwright
Abstract
Emergent BioSolutions, best known for its prophylactic anthrax vaccine BioThrax® (anthrax vaccine adsorbed), has acquired Trubion Pharmaceuticals in order to expand its pipeline beyond infectious diseases and into oncology and autoimmune diseases.
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.